An Open-Label, Multicenter, Single Arm QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors.

Trial Profile

An Open-Label, Multicenter, Single Arm QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2012

At a glance

  • Drugs Eribulin (Primary)
  • Indications Solid tumours
  • Focus Pharmacodynamics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 12 Apr 2012 Actual patient number is 26 according to ClinicalTrials.gov.
    • 30 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top